[PDF] Top 20 Desafíos en el diagnóstico de sífilis congénita

... eral vision, near activities, mental health, and composite score at 3 months, and showed a further significant improvement in distance activities, color vision, and peripheral vision at 12 ...in ... See full document

... of vision in stage 2 and the subsequent non-significant improvement of vision and significant improvement in CRT after AFL loading could be under ...treated using a PRN ...years using OCT ... See full document

... high quality control by payers (such as the situation in the UK) means that physicians adhere to protocols for monthly monitoring (including injections being around or above seven in the first year); however, this ... See full document

... underwent intravitreal injections of ranibizumab for new-onset exudative AMD between March 2010 and January 2013 at Ba ş kent University School of Medicine Department of Ophthalmology were reviewed ... See full document

... Off-label systemically administered bevacizumab was studied in an uncontrolled open label trial in 18 patients with CNV due to AMD. It caused improvement in median visual acuity of 14 letters and substantial reduction in ... See full document

... This study included 1072 eyes of 540 patients. The P value for the association between sex and disease is <0.001, age and disease is <0.001. Mean age was 60.37(12.74) standard deviation years (range ... See full document

... on Ranibizumab or Aflibercept was decided at the practitioner’s discretion at first visit and under the assumption of similar efficacy as no proof of superiority for the one or the other substance in specific ... See full document

... the macular and peripapillary region may ...in macular and temporal peripapil- lary CT were significant while CT outside of macula showed no significant ... See full document

... thickness using SD-OCT and its pos- sible impact on visual ...one ranibizumab intravitreal injection (P < ...of ranibizumab in reduc- ing thickness and volume of retina, which ... See full document

... Background: Intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) now improve or stabilize visual acuity in a number of previously untreatable eye diseases, of which the main are ... See full document

... synthesis using SuperScript Choice System (Thermo Fisher ...(cRNA) using BioArray HighYield RNA transcript labeling kit (Enzo Life Sciences, Farmingdale, NY, ...fragmented using Sample Cleanup ... See full document

... Patients were examined 1 month after injection and monthly thereafter. At each follow-up visit, BCVA measure- ment and OCT were performed, while FA was done only at the examiner’s discretion and not at every ... See full document

... the ranibizumab only group that had remarkably large visual gains (55 and 63 ...the ranibizumab only ...of ranibizumab only ...maintenance regimen must also be considered as a possible cause ... See full document

... Patients who had received previous treatment, transferred to another trust, or who subsequently had another diagnosis were excluded from our analysis, as were patients who had no more than the three treatments in the ... See full document

... Low Vision Ques- tionnaire [MLVQ] [118]) ...low vision care with enhanced regi- mens but found that no benefit accrued from the addi- tional help ...low vision care followed by additional teaching ... See full document

... fingers vision was recorded as logMAR 2 and hand movements as logMAR ...SMH using disc diameters was assessed from preoperative ...of intravitreal RZB injections in the 12 months of follow up were ... See full document

... worse vision, and therefore after treatment with ranibizu- mab QALYs accrued ...of ranibizumab compared to sham injection in MARINA was virtually identical to the efficacy of ranibizumab ... See full document

... ranibizumab tachyphylaxis, there is no established protocol for aflibercept treatment. In this study, five eyes showed increased intra/subretinal fluid at 8 weeks after IVA. This high recurrence rate suggests the ... See full document

... Moisseiev et al were able to demonstrate that differ- ent types of syringes, despite having the same labelling, deliver different volumes and thus deviate signi fi cantly from the values that the surgeon would like to ... See full document

... mean age: 72.7 ± 7.5 years) who underwent the treatment with intravitreal injection of ranibizumab for 3 years from 2010 to 2013 at the Department of Ophthalmology, Osaka Medical College, ... See full document